Other studies showed that the simultaneous inhibition of CDK12 and CDK13 suppresses tumorigenic features in leukemia [64], ovarian cancer [65] and triple-negative breast cancer [33]. This evidence concerns the gene CDK13 and triple-negative breast carcinoma.